Gonadorelin
Also referenced as: GnRH, LHRH, Factrel, Lutrepulse, Gonadorelin compounded
Synthetic gonadotropin-releasing hormone, used diagnostically and increasingly in compounded hormonal practice.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- Not FDA Approved
Compounded gonadorelin products are not FDA-approved. Historical human products included Factrel for diagnostic gonadotropin assessment and Lutrepulse for ovulation induction in hypothalamic GnRH deficiency. These discontinued products do not establish approval of compounded formulations or fertility preservation during testosterone therapy.
- Human data
- Yes
No registered clinical trials identified
- Last reviewed
- October 27, 2026
Overview
Gonadorelin is identical to natural GnRH, the hypothalamic decapeptide that drives pituitary LH and FSH release in pulses.
Its pharmacology is unambiguous; the question is whether the newer compounded uses discussed in men's health clinics are supported by outcome evidence. Largely, they are not.
Why It's Being Studied
- Diagnostic assessment of pituitary gonadotropin reserve.
- Maintenance of testicular function during exogenous testosterone use (compounded, off-label).
- Fertility and hypogonadotropic hypogonadism.
Mechanism of Action
It is the hormone signal that tells the pituitary to stimulate the testes or ovaries, given in short pulses.
Gonadorelin binds pituitary GnRH receptors, triggering LH and FSH release. Pulsatile administration preserves receptor sensitivity; continuous exposure causes receptor downregulation and gonadotropin suppression — the basis of GnRH agonist therapy in hormone-sensitive disease.
The hypothalamic–pituitary–gonadal axis
Tap each stage to see what happens.
Background: Hormonal Research
Hormonal peptides act on the hypothalamic–pituitary axes that govern reproduction, stress and growth.
These axes rely on pulsed signalling — the same molecule can stimulate or suppress depending on timing and duration.
Research Areas & Routes Studied
- Gonadotropin function
- Fertility
- Testicular function
- Subcutaneous injection
- Intravenous (diagnostic)
Evidence Summary
Long-standing human use as a diagnostic and fertility agent with established pharmacology, though modern outcome trials for newer community uses are absent.
Higher tiers carry more weight. Filled tiers have evidence for Gonadorelin; tap to read it.
- Diagnostic use is well established in endocrinology.
- Evidence for maintaining fertility during testosterone therapy relies heavily on extrapolation and clinical experience rather than randomised trials.
3 cited sources.
- Regulatory document1
- Prescribing label1
- Narrative review1
Human clinical evidence
- Diagnostic use is well established in endocrinology.
- Evidence for maintaining fertility during testosterone therapy relies heavily on extrapolation and clinical experience rather than randomised trials.
Observational evidence
- Compounded clinical use is common but poorly documented in the literature.
Reported Adverse Events in Research
- Headache, nausea, flushing, abdominal discomfort.
- Injection-site reactions; rare hypersensitivity.
- Continuous rather than pulsatile exposure can suppress rather than stimulate the axis.
Limitations of Current Evidence
- Short half-life makes dosing schedules critical and hard to standardise.
- Randomised evidence for current off-label uses is lacking.
How to Read This Research
- Was dosing pulsatile or continuous?
- Were hormones and fertility markers followed after stopping?
- Continuous stimulation can shut an axis down rather than activate it.
- Short studies rarely capture long-term hormonal effects.
- GnRH
- Gonadotropin-releasing hormone.
- LH / FSH
- Pituitary hormones that drive gonadal function.
Compare With Other Compounds
| Gonadorelin | Semaglutide | |
|---|---|---|
| Evidence grade | B — Moderate Human Evidence | A — Strong Clinical Evidence |
| Regulatory status | Not FDA Approved | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | None identified | Registered trials exist |
| Research routes | Subcutaneous injection, Intravenous (diagnostic) | Subcutaneous injection, Oral tablet (approved form) |
| Cited sources | 3 | 4 |
Frequently Asked Questions
Why It Is Used
- Sexual Health
Libido and Sexual Function
One of the few categories where the leading compound is FDA approved — and where its close relative is a clear example of what unselective signalling costs.
Read the case study
Research References
- Regulatory document
Historical human Factrel label approval record
- Prescribing label
Gonadorelin diagnostic labelling records
- Narrative review
GnRH physiology and pulsatile administration